dc.creatorDurovni, B.
dc.creatorCavalcante, S.
dc.date2019-07-08T14:39:32Z
dc.date2019-07-08T14:39:32Z
dc.date2018
dc.date.accessioned2023-09-26T22:48:44Z
dc.date.available2023-09-26T22:48:44Z
dc.identifierDUROVNI, Betina; CAVALCANTE, Solange. Preventive therapy for HIV-associated tuberculosis. Current Opinion in HIV and AIDS, v. 13, n. 6, p. 507-511, Nov. 2018.
dc.identifier1746-630X
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/33879
dc.identifier10.1097/COH.0000000000000504
dc.identifier1746-6318
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8883487
dc.descriptionPurpose of review: Tuberculosis (TB) remains the leading cause of death in people living with HIV (PLHIV) despite the achievements in antiretroviral therapy coverage. TB preventive therapy (TPT) has proved efficacy but has been neglected and poorly implemented. We reviewed recent publications and guidelines about TPT in PLHIV. Recent findings: High-quality studies showed that TPT has a durable effect, over 5 years, preventing TB and all-cause mortality. There is new evidence showing the noninferiority of shorter, rifamycin-based regimens of TPT increasing the options for treatment. Recent studies describing robust implementation in different settings showed promising results for feasibility, tolerance, retention, and cost-effectiveness. New WHO recommendations, unifying previous versions, have been released to guide countries implementation. Summary: New evidence support the scale up of TPT for PLHIV globally, further studies are needed to bring more evidence for specific populations, like pregnant women and for drug–drug interactions with antiretroviral agents.
dc.description2020-07-08
dc.formatapplication/pdf
dc.languageeng
dc.publisherLippincott, Williams & Wilkins
dc.rightsopen access
dc.subjectHIV
dc.subjectLatent tuberculosis infection
dc.subjectTuberculosis preventive therapy
dc.titlePreventive therapy for HIV-associated tuberculosis
dc.typeArticle


Este ítem pertenece a la siguiente institución